Cargando…

Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial

OBJECTIVES: The primary endpoint of the pivotal phase III study of infliximab (IFX) s.c. demonstrated non-inferiority of s.c. to i.v. IFX, based on 28-joint DAS-CRP (DAS28-CRP) improvement at week (W) 22 (NCT03147248). This post-hoc analysis investigated whether numerical differences in efficacy out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantin, Arnaud, Caporali, Roberto, Edwards, Christopher J, Fonseca, João Eurico, Iannone, Florenzo, Keystone, Edward, Schulze-Koops, Hendrik, Kwon, Taek, Kim, Seungmin, Yoon, SangWook, Kim, Dong-Hyeon, Park, Gahee, Yoo, Dae Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393429/ https://www.ncbi.nlm.nih.gov/pubmed/36534825 http://dx.doi.org/10.1093/rheumatology/keac689

Ejemplares similares

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
por: Combe, Bernard, et al.
Publicado: (2021)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
por: Iannone, Florenzo, et al.
Publicado: (2022)

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
por: D’Haens, Geert, et al.
Publicado: (2023)

Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
por: Baik, Deborah, et al.
Publicado: (2022)

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis
por: Vena, Gino Antonio, et al.
Publicado: (2018)

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
por: Burdge, Gemma, et al.
Publicado: (2022)

A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab
por: Favia, Gianfranco, et al.
Publicado: (2017)

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
por: Bouhnik, Yoram, et al.
Publicado: (2022)

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
por: Smith, Philip J, et al.
Publicado: (2022)

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
por: Carbery, Isabel, et al.
Publicado: (2023)

Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
por: Cerna, Karin, et al.
Publicado: (2023)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

Lymphopenia and autoimmune diseases
por: Schulze-Koops, Hendrik
Publicado: (2004)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
por: Hur, Gyu, et al.
Publicado: (2018)

Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
por: Mueller, Ruediger B., et al.
Publicado: (2022)

Chemerin/ChemR23 pathway: a system beyond chemokines
por: Iannone, Florenzo, et al.
Publicado: (2011)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells
por: Dodeller, Francis, et al.
Publicado: (2006)

IgG4-related sialadenitis: IgG4 is helpful, but biopsies are still crucial
por: Witte, Torsten, et al.
Publicado: (2015)

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
por: Schulze-Koops, Hendrik, et al.
Publicado: (2017)

COVID-19 vaccination in individuals with inflammatory rheumatic diseases
por: Skapenko, Alla, et al.
Publicado: (2022)

Management of a patient with common variable immunodeficiency and hepatopathy
por: Grümme, Lea, et al.
Publicado: (2023)

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
por: Bobbio-Pallavicini, Francesca, et al.
Publicado: (2004)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

1.5 Decades Later: Bearing fruits from the ACR/EULAR exchange Program
por: Cron, Randy Q, et al.
Publicado: (2011)

Where is biological therapy going?
por: Schulze-Koops, Hendrik, et al.
Publicado: (2000)

22nd European Workshop for Rheumatology Research, Leiden, The Netherlands, 28 February–3 March 2002
por: Cope, Andrew P, et al.
Publicado: (2002)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
por: Stamm, Tanja Alexandra, et al.
Publicado: (2018)

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
por: Little, Robert D., et al.
Publicado: (2022)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic
por: McGoran, John, et al.
Publicado: (2021)

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
por: Schulze-Koops, Hendrik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s9nrumnb2lipl6d1h8oeupfd0p